These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36906604)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled trial of prescribed heroin in the treatment of opioid addiction.
    March JC; Oviedo-Joekes E; Perea-Milla E; Carrasco F;
    J Subst Abuse Treat; 2006 Sep; 31(2):203-11. PubMed ID: 16919749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England.
    Riley F; Harris M; Poulter HL; Moore HJ; Ahmed D; Towl G; Walker T
    Harm Reduct J; 2023 May; 20(1):66. PubMed ID: 37173697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.
    Oviedo-Joekes E; Guh D; Marchand K; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
    Subst Abuse Treat Prev Policy; 2014 Jun; 9():23. PubMed ID: 24908387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment.
    Poulter HL; Walker T; Ahmed D; Moore HJ; Riley F; Towl G; Harris M
    Int J Drug Policy; 2023 Jun; 116():104025. PubMed ID: 37062231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of time-limited parenteral hydromorphone in people with treatment-resistant injecting opioid use disorder: a protocol for a single-site, uncontrolled, open-label study to assess feasibility, safety and cost.
    Rodgers C; Siefried KJ; Ritter A; Belackova V; Treloar C; Jauncey M; Ezard N; Roberts D; Steele M; van den Brink W; Strang J; Oviedo-Joekes E; Lintzeris N; Dunlop AJ; Bell J
    BMJ Open; 2024 Aug; 14(8):e082553. PubMed ID: 39097309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review.
    F Martins ML; Wilthagen EA; Oviedo-Joekes E; Beijnen JH; de Grave N; Uchtenhagen A; Beck T; Van den Brink W; Schinkel AH
    Drug Alcohol Depend; 2021 Oct; 227():108984. PubMed ID: 34482044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: associated health gains and harm reductions.
    Metrebian N; Shanahan W; Wells B; Stimson GV
    Med J Aust; 1998 Jun; 168(12):596-600. PubMed ID: 9673620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain.
    Coffin PO; Rowe C; Oman N; Sinchek K; Santos GM; Faul M; Bagnulo R; Mohamed D; Vittinghoff E
    PLoS One; 2020; 15(5):e0232538. PubMed ID: 32365132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
    Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opioid PrEscRiptions and usage After Surgery (OPERAS): protocol for a prospective multicentre observational cohort study of opioid use after surgery.
    TASMAN Collaborative Project Management Group
    BMJ Open; 2022 Nov; 12(11):e063577. PubMed ID: 36332960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of orally administered diacetylmorphine substitution treatment.
    Frick U; Rehm J; Zullino D; Fernando M; Wiesbeck G; Ammann J; Uchtenhagen A
    Eur Addict Res; 2010; 16(3):131-8. PubMed ID: 20424457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.
    Oviedo-Joekes E; Palis H; Guh D; Marsh DC; MacDonald S; Harrison S; Brissette S; Anis AH; Schechter MT
    J Addict Med; 2019; 13(5):354-361. PubMed ID: 30747750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis.
    Boyd S; Ivsins A; Murray D
    Int J Drug Policy; 2020 Apr; 78():102690. PubMed ID: 32278265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program.
    Gyr E; Brenneisen R; Bourquin D; Lehmann T; Vonlanthen D; Hug I
    Int J Clin Pharmacol Ther; 2000 Oct; 38(10):486-91. PubMed ID: 11073290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
    Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
    Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.
    Huhn AS; Strain EC; Tompkins DA; Dunn KE
    Drug Alcohol Depend; 2018 Dec; 193():142-147. PubMed ID: 30384321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.